Gx1-conjugated endostar nanoparticle: a new drug delivery system for anti-colorectal cancer in vivo

In this study we describe a new theranostic nanostytem to combine those functions together. GX1, the peptide identified by phage display technology, is a tumor vasculature endothelium specific ligand. Endostar, a novel recombinant human endostatin, has been proved to inhibit tumor angiogenesis. In this study, Endostar-loaded PLA nanoparticles (EPNPs) were first prepared, and then GX1 was coupled to the surface of EPNPs for targeting therapy, last a near infrared (NIR) dye IRDye 800CW was conjugated to the surface of EPNPs for monitoring the biodistributon. This GX1-EPNPs-NIR dye IRDye 800CW (GEN) multifunction drug delivery system not only facilitates efficient delivery of chemotherapeutic agents to tumor site, while minimizing systemic toxicity and side effects, but also enables to real time monitor tumor targeting in vivo. Compare to the Endostar and EPNPs, the GEN inhibited the subcutaneous colon tumor more obviously both in tumor volume and bioluminescence imaging (BLI) light intensity during the 10 days drug treatment.

[1]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[2]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[3]  Li Wang,et al.  A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy , 2009, BMC Cell Biology.

[4]  Peter S. Conti,et al.  Evaluation of 64Cu Labeled GX1: A Phage Display Peptide Probe for PET Imaging of Tumor Vasculature , 2012, Molecular Imaging and Biology.

[5]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[6]  Na Lu,et al.  Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. , 2007, Biochemical and biophysical research communications.

[7]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[8]  Sanjiv S Gambhir,et al.  Theranostic nanomedicine. , 2011, Accounts of chemical research.

[9]  Ralph Weissleder,et al.  Near-infrared fluorescence: application to in vivo molecular imaging. , 2010, Current opinion in chemical biology.

[10]  Fan Wang,et al.  Optical Imaging of Integrin αvβ3 Expression with Near-Infrared Fluorescent RGD Dimer with Tetra(ethylene glycol) Linkers , 2010 .

[11]  Kai Yang,et al.  In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. , 2012, ACS nano.

[12]  Jason R McCarthy,et al.  The future of theranostic nanoagents. , 2009, Nanomedicine.

[13]  E M Sevick-Muraca,et al.  Translation of near-infrared fluorescence imaging technologies: emerging clinical applications. , 2012, Annual review of medicine.